Clinical Trial Update: Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating subcutaneous secukinumab for chronic plaque psoriasis, comparing it with etanercept and placebo, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Etanercept (etanercept)
• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: WITHDRAWN